David Zaccardelli compensation by year
Verona Pharma Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $524,842 | $819,568 | $873,015 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $4,133,500 | $5,324,000 | $18,089,500 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $497,297 | $440,705 | $480,158 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $27,501 | $13,200 | $13,800 |
| Total | $5,183,140 | $6,597,473 | $19,456,473 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Verona Pharma plc DEF 14A filed March 18, 2025, accession 0001104659-25-025050, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Verona Pharma plc filed document, accession 0001104659-25-025050. Every figure is read from that document and cited to the page and table it appears in. Filed March 18, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 300,000 | $13,932,000 | — |
| RSU | 225,000 | $10,449,000 | — |
| RSU | 175,000 | $8,127,000 | — |
| RSU | 100,000 | $4,644,000 | — |
| RSU | 75,000 | $3,483,000 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Verona Pharma plc's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
31 Form 4 lines since the FY2024 proxy (filed March 18, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-10-07 | Disposition to the issuer | — | 12,176,144 | — | 0 |
| 2025-10-07 | Disposition to the issuer | — | 3,285,280 | — | 0 |
| 2025-10-07 | Exercise or conversion | — | 3,285,280 | — | 3,285,280 |
| 2025-10-07 | Exercise or conversion derivative | — | 389,792 | — | 0 |
| 2025-10-07 | Exercise or conversion derivative | — | 445,536 | — | 0 |
| 2025-10-07 | Exercise or conversion derivative | — | 1,649,952 | — | 0 |
| 2025-10-07 | Exercise or conversion derivative | — | 800,000 | — | 0 |
| 2025-10-07 | Grant or award derivative | — | 1,649,952 | — | 1,649,952 |
The 8 most recent of 31 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Verona Pharma’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| David Zaccardelli · this page | President and Chief Executive Officer | $19,456,473 |
| Mark Hahn | Chief Financial Officer | $19,005,415 |
| Andrew Fisher | General Counsel | $10,821,932 |
| Kathleen Rickard | Chief Medical Officer | $7,509,563 |
| Claire Poll | Former General Counsel | $326,023 |
The full Verona Pharma compensation record
free company briefThis page is one person within Verona Pharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Verona Pharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Verona Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.